From VALGEN’s web site clicke here:

Value Addition through Genomics and GE3LS or VALGEN research project is co-led by Dr. Peter W.B.
Phillips , a professor with the Johnson-Shoyama Graduate School of Public Policy at the University of Saskatchewan and Dr. David Castle, Chair of Innovation in the Life Sciences at the University of Edinburgh. The project answers three critical questions about the future of genomics. When any innovation emerges, those questions are: Who owns it? Who controls it? Who wants it?

The VALGEN team will investigate how new discoveries leave the laboratory as intellectual property, and the legal and business tools surrounding that property. It will also identify models for governing these new products, and finally, determine how Canadians feel about new crops and bioproducts. This leading-edge research will inform future public policy that regulates how innovative products move from the laboratory to the marketplace.

The VALGEN team includes researchers from across the country from the University of British Columbia, University of Calgary, University of Regina, University of Ottawa, McGill University (Montreal), and Laval University (Quebec City).

Over 100 students and employees, as well as 60 industrial and government partners contributing to research design and development, will work with the VALGEN project.

Academic partners include The University of Edinburgh (Scotland), Kluyver Center for Genomics (The Netherlands), and the Universite de Versailles Saint-Quentin-en-Yvelines in Paris.

VALGEN is supported by Genome Canada and managed by Genome Prairie. Major funding partners include the Government of Saskatchewan, Western Economic Diversification, Genome Alberta, Genome BC, Genome Quebec, the Canola Council of Canada, and SRC Holdings Ltd. VALGEN is a four year project that was initiated October 1, 2009.

DISCLOSURE: I am a member of the Scientific Advisory Board for the VALGEN project. This is quite an exciting project pushing the boundaries where economic, ethical, environmental and legal aspects of biotechnology merge and where they operate.